ReviewCurrent cancer drug targets2026
Regulatory Effect of Non-Coding RNAs on Programmed Cell Death in Melanoma: Novel Therapeutic Crosstalk for Targeted Therapy.
Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma, one of the most fatal and aggressive types of skin cancer, is a malignant tumor created from pigment-producing cells called melanocytes. The morbidity and incidence rate of melanoma are increasing around the world. Considering all developments in diagnostic and therapeutic approaches, early diagnosis and more effective targeted therapies are still urgent for melanoma. Non-coding RNAs (ncRNAs), including microRNAs and long non-coding RNAs, are key role players in fundamental cellular processes and have various biological properties. It has been demonstrated that the dysregulation of these biomarkers contributes to melanoma pathogenesis. Furthermore, programmed cell death (PCD), as an important cellular event, has been shown to play a role in the initiation and progression of cutaneous melanoma. Recent investigations have reported that the interplay between ncRNAs and PCD can be considered a novel choice for targeted therapy in melanoma. Thus, this review discusses PCD-related ncRNAs in melanoma, focusing on underlying pathways.
Indexed as
Identifiers
40017243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.